Alexion Pharmaceuticals last week reached...

...a settlement with Amgen that will keep its blockbuster complement C5 inhibitor Soliris from seeing U.S. generic competition until 2025. Amgen had previously challenged Alexion's Soliris paroxysmal nocturnal hemoglobinuria (PNH) patents after seeing promising clinical results for its own biosimilar, which is still undergoing trials. For the treatment of neuromyelitis optica spectrum disorder, Soliris currently holds preferred status under the pharmacy benefit for just 2% of covered lives, growing to 15% with prior authorization and/or step therapy. Soliris is not covered or not listed for 40% of all covered lives.

SOURCE: MMIT Analytics, as of 6/3/20